Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marielle Eerdekens

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Journal of Clinical Psychopharmacology|May 17, 2006
To what extent do the PANSS and CGI-S overlap?Jonathan Rabinowitz, Angelika Mehnert, Marielle Eerdekens
Pain Physician|September 23, 2021
Treatment Impact on Patient-Reported Outcomes in Peripheral Neuropathic Pain: Comparing Single Intervention With Topical High-Concentration Capsaicin to Daily Oral PregabalinEric Viel, Marielle Eerdekens, Prashanth Kandaswamy
Journal of Child and Adolescent Psychopharmacology|June 14, 2006
Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerabilityMagali Reyes, Jan Croonenberghs, Ilse Augustyns, et al.
The British Journal of Psychiatry : the Journal of Mental Science|July 4, 2006
Premorbid functioning and treatment response in recent-onset schizophreniaJonathan Rabinowitz, Philip D Harvey, Marielle Eerdekens, et al.
The American Journal of Psychiatry|October 4, 2005
Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trialPhilip D Harvey, Jonathan Rabinowitz, Marielle Eerdekens, et al.
The American Journal of Psychiatry|March 4, 2006
A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disordersMagali Reyes, Jan Buitelaar, Paz Toren, et al.
European Child & Adolescent Psychiatry|March 9, 2006
Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension studyMagali Reyes, Roza Olah, Krisztina Csaba, et al.
Clinical Therapeutics|October 13, 2004
In vitro effects of risperidone and 9-hydroxy-risperidone on human platelet function, plasma coagulation, and fibrinolysisFred De Clerck, Yves Somers, Erik Mannaert, et al.
The American Journal of Psychiatry|April 2, 2004
Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQRobert L Findling, Michael G Aman, Marielle Eerdekens, et al.
Journal of Affective Disorders|November 24, 2004
Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorderRobert Lasser, Cynthia A Bossie, Georges Gharabawi, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Journal of Clinical Psychopharmacology|May 17, 2006
To what extent do the PANSS and CGI-S overlap?Jonathan Rabinowitz, Angelika Mehnert, Marielle Eerdekens
Pain Physician|September 23, 2021
Treatment Impact on Patient-Reported Outcomes in Peripheral Neuropathic Pain: Comparing Single Intervention With Topical High-Concentration Capsaicin to Daily Oral PregabalinEric Viel, Marielle Eerdekens, Prashanth Kandaswamy
Journal of Child and Adolescent Psychopharmacology|June 14, 2006
Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerabilityMagali Reyes, Jan Croonenberghs, Ilse Augustyns, et al.
The British Journal of Psychiatry : the Journal of Mental Science|July 4, 2006
Premorbid functioning and treatment response in recent-onset schizophreniaJonathan Rabinowitz, Philip D Harvey, Marielle Eerdekens, et al.
The American Journal of Psychiatry|October 4, 2005
Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trialPhilip D Harvey, Jonathan Rabinowitz, Marielle Eerdekens, et al.
The American Journal of Psychiatry|March 4, 2006
A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disordersMagali Reyes, Jan Buitelaar, Paz Toren, et al.
European Child & Adolescent Psychiatry|March 9, 2006
Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension studyMagali Reyes, Roza Olah, Krisztina Csaba, et al.
Clinical Therapeutics|October 13, 2004
In vitro effects of risperidone and 9-hydroxy-risperidone on human platelet function, plasma coagulation, and fibrinolysisFred De Clerck, Yves Somers, Erik Mannaert, et al.
The American Journal of Psychiatry|April 2, 2004
Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQRobert L Findling, Michael G Aman, Marielle Eerdekens, et al.
Journal of Affective Disorders|November 24, 2004
Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorderRobert Lasser, Cynthia A Bossie, Georges Gharabawi, et al.
Pageof 3